Data as of Oct 21
| +0.48 / +1.07%|
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
|Lars Rebien SÃ¸rensen||Chief Executive Officer|
|KÃ¥re Schultz||President & Chief Operating Officer|
|Jesper Brandgaard||Chief Financial Officer & Executive Vice President|
|Lars Fruergaard JÃ¸rgensen||Chief Information Officer & Executive VP|
|Mads Krogsgaard Thomsen||Chief Science Officer & Executive Vice President|